Soligenix, Inc. Stock News
$0.32
5.88%
Nasdaq, Nov 10, 03:59 pm EST.
Closed.
Soligenix, Inc. Stock News
PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended September 30, 2026.
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended June 30, 2026.
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted to...
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
